Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04074967
Title Study of ARRY-614 Plus Either Nivolumab or Ipilimumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jason J. Luke, MD
Indications

Advanced Solid Tumor

melanoma

renal cell carcinoma

Therapies

Ipilimumab + Pexmetinib

Nivolumab + Pexmetinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.